RecruitingPhase 1NCT07655518

A Positron Emission Tomography Study to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult Participants

A Phase 1, Open-label, Positron Emission Tomography (PET) Imaging Study to Evaluate M4 Muscarinic Acetylcholine Receptor Occupancy in the Central Nervous System Using [11C]MK-6884 PET Tracer Before and After Oral Administration of Multiple Doses of BMS-986521 in Healthy Adult Participants


Sponsor

Bristol-Myers Squibb

Enrollment

12 participants

Start Date

Jun 25, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult Participants


Eligibility

Min Age: 18 YearsMax Age: 55 Years

Inclusion Criteria2

  • Participants must be healthy male and female (as assigned at birth) who are individuals not of childbearing potential (INOCBP) without clinically significant deviation from normal in medical history, PE, 12-lead ECG, and clinical laboratory assessments.
  • Participants must have a BMI of 18 to 30 kg/m\^2, inclusive, and total body weight ≥ 50 kg.

Exclusion Criteria3

  • Participants must not have presence or history of any clinically relevant abnormality, condition, or disease-CNS, cardiovascular, renal, hepatic, hematologic, GI, endocrine, pulmonary, psychiatric, neurologic (eg, seizure disorder), or immunologic.
  • Participants must not have history of rhabdomyolysis.
  • Participants must not have current or recent (within 3 months of study intervention administration) clinically significant GI disease.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBMS-986521

Specified dose on specified days


Locations(1)

Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg

Leuven, Belgium

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07655518


Related Trials